La Jolla Pharmaceutical Co. (LJP) moved ever so cautiously into its first phase III trial in more than a decade, advancing lead compound LJPC-501 (angiotensin II) into ATHOS (Angiotensin II for the Treatment of High-Output Shock) 3 to treat catecholamine-resistant hypotension (CRH).